支持国际骨髓瘤工作组指南的研究中多发性骨髓瘤黑人患者代表性不足

IF 2 Q3 HEALTH POLICY & SERVICES Journal of Cancer Policy Pub Date : 2023-09-01 DOI:10.1016/j.jcpo.2023.100433
Suhib Fahmawi , Carolina Schinke , Sharmilan Thanendrarajan , Maurizio Zangari , John D. Shaughnessy Jr. , Fenghuang Zhan , Frits van Rhee , Samer Al Hadidi
{"title":"支持国际骨髓瘤工作组指南的研究中多发性骨髓瘤黑人患者代表性不足","authors":"Suhib Fahmawi ,&nbsp;Carolina Schinke ,&nbsp;Sharmilan Thanendrarajan ,&nbsp;Maurizio Zangari ,&nbsp;John D. Shaughnessy Jr. ,&nbsp;Fenghuang Zhan ,&nbsp;Frits van Rhee ,&nbsp;Samer Al Hadidi","doi":"10.1016/j.jcpo.2023.100433","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Multiple myeloma (MM) is more common in Black persons when compared to non-Hispanic White persons. The International Myeloma Working Group (IMWG) provides consensus for diagnosis and treatment of MM. Our study aimed to assess the racial composition of supporting studies used by IMWG to publish their guidelines</p></div><div><h3>Methods</h3><p>We performed a cross sectional study that included all IMWG publications up to July 2022. References cited in each publication were reviewed. Review articles, comments, editorials, case reports, and animal-based studies were excluded.</p></div><div><h3>Results</h3><p>A total of 59 IMWG publications with 3956 references were reviewed. Final analysis included 2047 references of which 39 % (n = 804) were clinical trials, 35 % (n = 712) were observational studies, 20 % (n = 401) were diagnostic and or genetic testing-based studies, 3 % (n = 65) were population-based analysis and 3 % (n = 65) classified as others. Only 10.4 % of included references (n = 213/2047) reported race/ethnicity of studied patients. The total number of patients in all referenced studies were 5,747,920, only 2.6 % (n = 150,790) black patients. Of the trials referenced and done exclusively in the US, 41 out of 282 (14.5 %) reported race/ethnicity with a total number of patients of 38,050 of which 2493 (6.5 %) were black patients.</p></div><div><h3>Conclusion</h3><p>IMWG guidelines were based mainly on studies that did not include enough Black patients. Guidelines should consider inclusion of observational, diagnostic and population-based studies with more black patients to allow for better reflection of disease prevalence, clinical characteristics and/or outcomes.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"37 ","pages":"Article 100433"},"PeriodicalIF":2.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines\",\"authors\":\"Suhib Fahmawi ,&nbsp;Carolina Schinke ,&nbsp;Sharmilan Thanendrarajan ,&nbsp;Maurizio Zangari ,&nbsp;John D. Shaughnessy Jr. ,&nbsp;Fenghuang Zhan ,&nbsp;Frits van Rhee ,&nbsp;Samer Al Hadidi\",\"doi\":\"10.1016/j.jcpo.2023.100433\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Multiple myeloma (MM) is more common in Black persons when compared to non-Hispanic White persons. The International Myeloma Working Group (IMWG) provides consensus for diagnosis and treatment of MM. Our study aimed to assess the racial composition of supporting studies used by IMWG to publish their guidelines</p></div><div><h3>Methods</h3><p>We performed a cross sectional study that included all IMWG publications up to July 2022. References cited in each publication were reviewed. Review articles, comments, editorials, case reports, and animal-based studies were excluded.</p></div><div><h3>Results</h3><p>A total of 59 IMWG publications with 3956 references were reviewed. Final analysis included 2047 references of which 39 % (n = 804) were clinical trials, 35 % (n = 712) were observational studies, 20 % (n = 401) were diagnostic and or genetic testing-based studies, 3 % (n = 65) were population-based analysis and 3 % (n = 65) classified as others. Only 10.4 % of included references (n = 213/2047) reported race/ethnicity of studied patients. The total number of patients in all referenced studies were 5,747,920, only 2.6 % (n = 150,790) black patients. Of the trials referenced and done exclusively in the US, 41 out of 282 (14.5 %) reported race/ethnicity with a total number of patients of 38,050 of which 2493 (6.5 %) were black patients.</p></div><div><h3>Conclusion</h3><p>IMWG guidelines were based mainly on studies that did not include enough Black patients. Guidelines should consider inclusion of observational, diagnostic and population-based studies with more black patients to allow for better reflection of disease prevalence, clinical characteristics and/or outcomes.</p></div>\",\"PeriodicalId\":38212,\"journal\":{\"name\":\"Journal of Cancer Policy\",\"volume\":\"37 \",\"pages\":\"Article 100433\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213538323000504\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538323000504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

引言与非西班牙裔白人相比,多发性骨髓瘤在黑人中更常见。国际骨髓瘤工作组(IMWG)为MM的诊断和治疗提供了共识。我们的研究旨在评估IMWG用于发表其指南的支持性研究的种族组成。方法我们进行了一项横断面研究,包括截至2022年7月的所有IMWG出版物。对每份出版物中引用的参考文献进行了审查。综述文章、评论、社论、病例报告和基于动物的研究被排除在外。结果共查阅了59篇IMWG出版物,参考文献3956篇。最终分析包括2047篇参考文献,其中39%(n=804)为临床试验,35%(n=712)为观察性研究,20%(n=401)为基于诊断和/或基因检测的研究,3%(n=65)为基于人群的分析,3%(n=65)归类为其他研究。只有10.4%的纳入参考文献(n=213/2047)报告了研究患者的种族/民族。所有参考研究中的患者总数为5747920人,只有2.6%(n=150790)的黑人患者。在美国专门引用和进行的试验中,282人中有41人(14.5%)报告了种族/民族,患者总数为38050人,其中2493人(6.5%)是黑人患者。结论IMWG指南主要基于没有包括足够黑人患者的研究。指南应考虑纳入对更多黑人患者的观察性、诊断性和基于人群的研究,以便更好地反映疾病流行率、临床特征和/或结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines

Introduction

Multiple myeloma (MM) is more common in Black persons when compared to non-Hispanic White persons. The International Myeloma Working Group (IMWG) provides consensus for diagnosis and treatment of MM. Our study aimed to assess the racial composition of supporting studies used by IMWG to publish their guidelines

Methods

We performed a cross sectional study that included all IMWG publications up to July 2022. References cited in each publication were reviewed. Review articles, comments, editorials, case reports, and animal-based studies were excluded.

Results

A total of 59 IMWG publications with 3956 references were reviewed. Final analysis included 2047 references of which 39 % (n = 804) were clinical trials, 35 % (n = 712) were observational studies, 20 % (n = 401) were diagnostic and or genetic testing-based studies, 3 % (n = 65) were population-based analysis and 3 % (n = 65) classified as others. Only 10.4 % of included references (n = 213/2047) reported race/ethnicity of studied patients. The total number of patients in all referenced studies were 5,747,920, only 2.6 % (n = 150,790) black patients. Of the trials referenced and done exclusively in the US, 41 out of 282 (14.5 %) reported race/ethnicity with a total number of patients of 38,050 of which 2493 (6.5 %) were black patients.

Conclusion

IMWG guidelines were based mainly on studies that did not include enough Black patients. Guidelines should consider inclusion of observational, diagnostic and population-based studies with more black patients to allow for better reflection of disease prevalence, clinical characteristics and/or outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
期刊最新文献
Rapid diagnostic pathways for prostate cancer: A realist synthesis. Time in the U.S. and Colorectal Cancer Screening Adherence Among Diverse Immigrants. Overcoming barriers of cervical cancer elimination in India: A practice to policy level advocacy. Precision oncology implementation in a regional-based health care system: A professional consensus to define the pathway Analysis of 810 tweets from 25 unofficial ASCO representatives (Featured Voices) at ASCO 2024
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1